Argus Research
- Home
- ENTX
ENTX
Entera Bio Ltd.
as of 03-10-2026 3:58pm EST
$1.50
+$0.17
+12.41%
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
| Founded: | 2010 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 74.7M | IPO Year: | 2015 |
| Target Price: | $10.00 | AVG Volume (30 days): | 147.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | -19.35 |
| 52 Week Low/High: | $1.00 - $3.22 | Next Earning Date: | N/A |
| Revenue: | $181,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -76.33% | Revenue Growth (next year): | N/A |
| P/E Ratio: | 6.97 | Index: | N/A |
| Free Cash Flow: | -6821000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Entera Bio Ltd. (ENTX)
Ellis Sean
Buy
Director
ENTX Mar 5, 2026
Avg Cost/Share
$1.23
Shares
10,000
Total Value
$12,300.00
Owned After
188,098
SEC Form 4
Taitel Haya
Buy
Director
ENTX Feb 10, 2026
Avg Cost/Share
$1.48
Shares
7,500
Total Value
$11,100.00
Owned After
0
SEC Form 4
Germano Geno J
Buy
Director
ENTX Feb 10, 2026
Avg Cost/Share
$1.49
Shares
20,000
Total Value
$29,800.00
Owned After
0
SEC Form 4
Ellis Sean
Buy
Director
ENTX Feb 9, 2026
Avg Cost/Share
$1.24
Shares
18,000
Total Value
$22,320.00
Owned After
188,098
SEC Form 4
Toledano Miranda Jayne
Buy
Chief Executive Officer
ENTX Dec 29, 2025
Avg Cost/Share
$1.81
Shares
11,000
Total Value
$19,912.20
Owned After
426,575
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ellis Sean | ENTX | Director | Mar 5, 2026 | Buy | $1.23 | 10,000 | $12,300.00 | 188,098 | |
| Taitel Haya | ENTX | Director | Feb 10, 2026 | Buy | $1.48 | 7,500 | $11,100.00 | 0 | |
| Germano Geno J | ENTX | Director | Feb 10, 2026 | Buy | $1.49 | 20,000 | $29,800.00 | 0 | |
| Ellis Sean | ENTX | Director | Feb 9, 2026 | Buy | $1.24 | 18,000 | $22,320.00 | 188,098 | |
| Toledano Miranda Jayne | ENTX | Chief Executive Officer | Dec 29, 2025 | Buy | $1.81 | 11,000 | $19,912.20 | 426,575 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 14, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 14, 2025 · 100% conf.
AI Prediction SELL
1D
-4.60%
$2.59
5D
-10.34%
$2.44
20D
-3.16%
$2.63
Price: $2.72 Prob +5D: 0% AUC: 1.000
0001178913-25-003851
false000163809700-00000009722-532-7151Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary ShareENTXWNASDAQNASDAQ00016380972025-11-142025-11-140001638097entx:OrdinarySharesParValueOfNIS00000769Member2025-11-142025-11-140001638097entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember2025-11-142025-11-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2025
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Israel
001-38556
Not Applicable
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification)
Kiryat Hadassah, Minrav Building – Fifth Floor, Jerusalem, Israel 9112002
(Address of principal executive offices) (Zip Code)
+972-2-532-7151
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
ENTX
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 14, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated November 14, 2025 announcing the Company’s financial results and business updates for the three months ended September 30, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTERA BIO LTD.
Date: November 14, 2025
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 8, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 8, 2025
0001178913-25-002701
false000163809700-00000009722-532-7151Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary ShareENTXWNASDAQNASDAQ00016380972025-08-082025-08-080001638097entx:OrdinarySharesParValueOfNIS00000769Member2025-08-082025-08-080001638097entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember2025-08-082025-08-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 8, 2025
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Israel
001-38556
Not Applicable
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification)
KIRYAT HADASSAH, MINRAV BUILDING – FIFTH FLOOR, JERUSALEM, Israel 9112002
(Address of principal executive offices) (Zip Code)
+972-2-532-7151
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
ENTX
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 8, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated August 8, 2025 announcing the Company’s financial results and business updates for the three months ended June 30, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ENTERA BIO LTD.
Date: August 8, 2025
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer
2025 Q1 Q1 2025 Earnings
8-K May 9, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 9, 2025
0001178913-25-001673
false000163809700-00000009722-532-7151Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary ShareENTXWNASDAQNASDAQ00016380972025-05-092025-05-090001638097entx:OrdinarySharesParValueOfNIS00000769Member2025-05-092025-05-090001638097entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember2025-05-092025-05-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2025
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Israel
001-38556
Not Applicable
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification)
KIRYAT HADASSAH, MINRAV BUILDING – FIFTH FLOOR, JERUSALEM, Israel 9112002
(Address of principal executive offices) (Zip Code)
+972-2-532-7151
(Registrant’s Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
ENTX
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated May 9, 2025 announcing the Company’s financial results and business updates for the three months ended March 31, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENTERA BIO LTD.
Date: May 9, 2025
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer
Latest Entera Bio Ltd. News
ENTX Breaking Stock News: Dive into ENTX Ticker-Specific Updates for Smart Investing
Argus Research
Daily – Vickers Top Insider Picks for 03/05/2026
GlobeNewswire
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
📈
AI Sentiment
Highly Positive
9/10
Compare ENTX vs Leading Stocks
See how ENTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENTX Entera Bio Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.